BETA

4 Amendments of Carlos ZORRINHO related to 2016/2057(INI)

Amendment 78 #
Motion for a resolution
Recital D
D. whereas in addition to high prices, other barriers to access to medicines include shortages of essential medicines, the poor connection between clinical needs and research, reimbursement systems, access to healthcare professionals and diagnostics, unjustified administrative procedures, rigid patent rules and budget restrictions;
2016/10/21
Committee: ENVI
Amendment 311 #
Motion for a resolution
Paragraph 13
13. Believes that a fair price should cover the cost of the drug development and production, plus a margin of profit taking into account the public financing received in the first steps of the product development, if applicable;
2016/10/21
Committee: ENVI
Amendment 359 #
Motion for a resolution
Paragraph 16 a (new)
16a. Underlines the need for further cooperation at EU level to improve access to medicines;
2016/10/21
Committee: ENVI
Amendment 545 #
Motion for a resolution
Paragraph 29
29. Calls on the Commission and the Council to explore new measures to control prices, such as horizontal scanning and, coordinating joint procurements and the evolution of healthcare public expenditures;
2016/10/21
Committee: ENVI